Alnylam Pharmaceuticals, Inc. (ALNY) – What Are Researchers Saying About This Stock?

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been assigned a consensus rating of “Moderate Buy” from the twenty-six research firms that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and four have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $364.95.

Several analysts have issued reports on ALNY shares. Jefferies Financial Group upped their price target on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a research report on Tuesday, September 8th. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Zacks Research upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 5th. BMO Capital Markets restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Finally, Morgan Stanley dropped their target price on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a report on Friday, July 31st.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ALNY. MV Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $25,000. Toth Financial Advisory Corp acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $25,000. Burkett Financial Services LLC acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $37,000. CoreCap Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 744.4% during the 3rd quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 134 shares during the last quarter. Finally, Keating Financial Advisory Services Inc. bought a new position in Alnylam Pharmaceuticals during the second quarter worth $42,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Down 1.4%

NASDAQ:ALNY opened at $224.03 on Friday. The firm has a market capitalization of $29.98 billion, a price-to-earnings ratio of 41.64 and a beta of 0.28. Alnylam Pharmaceuticals has a twelve month low of $197.81 and a twelve month high of $485.36. The stock’s 50 day moving average price is $239.80 and its two-hundred day moving average price is $271.03. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter in the prior year, the firm posted ($0.51) EPS. The firm’s revenue for the quarter was up 66.9% compared to the same quarter last year. Equities research analysts expect that Alnylam Pharmaceuticals will post 6.66 earnings per share for the current fiscal year.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Promising Huntington’s disease results: Alnylam reported that investigational RNAi therapy brezosiran (ALN-HTT02) reduced mutant huntingtin by approximately 60% to 64% in an initial Phase 1b study. The company described the reduction as deep and durable, potentially supporting further development in a disease with significant unmet medical need. Alnylam brezosiran Phase 1b results
• Positive Sentiment: Potential pipeline expansion: Reports characterized brezosiran’s huntingtin knockdown as potentially best-in-class, and Alnylam plans to advance the program toward a pivotal trial. Success could broaden the company’s long-term growth beyond its marketed RNAi medicines. Alnylam plans pivotal Huntington’s trial
• Positive Sentiment: Analyst confidence remains strong: Raymond James reiterated its Strong Buy rating on ALNY. Separately, the reported consensus price target is $364.95, substantially above the level described in the provided market background. Raymond James Strong Buy rating
• Neutral Sentiment: Earnings expectations are favorable but unconfirmed: Zacks expects Alnylam to have a favorable setup for an earnings beat in its upcoming report. However, this is only an estimate and does not yet represent reported results. Alnylam earnings expectations
• Negative Sentiment: Clinical and valuation risks remain: Brezosiran is still in Phase 1b, so its efficacy, safety, durability and ability to succeed in a pivotal trial remain uncertain. The stock also trades well below its 200-day moving average, suggesting investors may still be discounting execution, development and valuation risks.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.